pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

artios PRESS RELEASE ARCHIVE

Feb 9, 2023

Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer

Aug 10, 2022

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

Jun 23, 2022

Artios Appoints Samantha Truex to Board of Directors

Apr 5, 2022

Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation

Nov 16, 2021

Artios Appoints Nora Brennan to Board of Directors and Audit Committee Chair

Sep 28, 2021

Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215

Jul 27, 2021

Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X

Jun 17, 2021

Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications

Apr 7, 2021

Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies

Apr 7, 2021

Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies

Apr 7, 2021

Feb 11, 2021

Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients

Jan 12, 2021

Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer

Dec 3, 2020

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

Nov 6, 2019

Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor

Sep 24, 2019

Artios Pharma Appoints Tania Dimitrova as Chief Business Officer and Expands Presence in the United States

Apr 1, 2019

Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer

Feb 11, 2019

Artios Pharma Announces Appointment of Professor Rajesh Chopra as Non-Executive Director

Aug 10, 2018

Artios Pharma Announces $84 Million (£65 Million) Series B Financing

Mar 5, 2018

Artios exercises option to in-license potential first-in-class nuclease development programme

Mar 5, 2018

Artios exercises option to in-license potential first-in-class nuclease development programme

Feb 26, 2018

Artios Pharma Appoints Pierre Legault as Chairman of its Board of Directors

Sep 21, 2016

Artios Pharma Company Launch and Fundraising of $33.2 Million to Focus on Novel DNA Damage Response (DDR) Cancer Therapies

Google Analytics Alternative